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1. Academic entrepreneurship in biotechnology
Innovative sectors of high technology are considered as one of the most
important elements of the modern economy. The biotechnology industry perfectly 
fulfills the criteria of belonging to sectors of this type, and by some researchers [1] 
its development is considered indispensable for the functioning of modern 
economy. In technologically advanced industries, progress is impossible without 
access to knowledge and innovation, the most important source of which are 
research and development (R&D) institutions – both parts of companies and state 
research and educational entities (higher education institutions). 
In the biotechnology sector, unlike any other industries related to innovation, 
the majority of innovations are created in dedicated research units – mainly 
universities [2]. Therefore, the basis for the development of this sector is an 
efficient knowledge dissemination process, enabling rapid penetration of the latest 
innovations in the economy. Landry et al. [3] distinguish three main diffusion paths 
in this case: fairs and conferences, the educational process of qualified employees 
and commercialization knowledge, skills. Commercialization takes place through: 
consulting services, research contracting, patenting (and subsequent sale of 
patents) and creating companies type of spin-off. The last one is the most important 
in the biotechnology industry forms [3]. 
Academic spin-off companies, which are the most important element of the 
biotechnology sector development, are in Poland at an initial stage of advancement. 
Activity of this type of endeavors remained unnoticed by the authorities and 
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business support organizations almost until the middle of the first decade of the 
21st century. It was only the inflow of European Union funds focused on the 
development of innovative enterprises and a specific “fashion for innovation” 
resulted in increased interest in spin-offs (the first publication dedicated to spin-
off companies in the high technology sectors, financed by Polish Agency for 
Enterprise Development – PARP, was issued in 2006). 
International experience, especially American, indicates the extension of 
entrepreneurship education, which has been present in business school programs 
for years, also for didactic offers of technical universities and exact sciences at 
universities. Research shows that especially students of technical faculties, 
enriched with knowledge in the field of starting a new business, have a better 
chance of success than graduates of economic studies. The leaders in academic 
entrepreneurship are such universities as the Massachusetts Institute of 
Technology (MIT) and Stanford University, which has developed specialized 
didactic programs in the field of technology entrepreneurship, widely used in academic 
centers around the world [4]. 
The entrepreneurial competences and the ability to create innovations and 
research are crucial in the development of academic entrepreneurship [5]. 
Universities and Research Institutes should seek to transfer technology to the 
private sector, and therefore capture the benefits of commercialization of their 
innovation and intellectual property rights (IPR), through a number of different 
mechanisms. Thus, academic entrepreneurship can be defined as the involvement 
of scientific institutions and people associated with them, which “have the ability 
to create and visualize opportunities, take control over the possibilities, absorb and 
organize the necessary resources leading to the creation of new goods” [6] and they 
have the ability to create innovative solutions, which develop or implement new 
or improved products, services, production processes, technologies, organizational 
processes and marketing techniques [7]. Academic entrepreneurship is inextricably 
linked to scientific research and commercialization of technology and knowledge. 
One of the instruments used to transfer knowledge and technologies to build 
academic entrepreneurship are spin-offs [8]. 
2. Spin-off entities 
A key element of the definition is the existence of commercialization based 
on intellectual property created at the parent university. On the other hand, forms 
of economic activity of scientific employees, in the case of which there are no 
intellectual property issues, are not treated as manifestations of academic 
entrepreneurship [9]. Matusiak [10] understands academic entrepreneurship much 
more broadly, as “all kinds of engagement of scientific institutions, auxiliary and 
administrative staff, PhD students and students in business” [11]. We deal with 
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widely understood manifestations of entrepreneurial activity of academic staff in 
various areas of cooperation between universities and business practice, the result 
of which is comer-cialization of research results, including cooperative forms of 
technology transfer based on licensing agreements, conducting research 
commissioned by industry, joint implementations, etc. [9]. 
According to a leading American researcher on academic entrepreneurship S. 
Shane [12], spin-offs are new companies created by members of the academic 
community in order to commercialize technology as an element of intellectual 
property created in the parent institution. 
According to the STI Review, the scope of the term “spin-off” varies between 
countries. In the United States, a spin-off is any new company that employs a 
public or university employee; or a student or graduate as one of the founders; 
which licenses technology from a university or public research center [13]. But 
also every new company that started operations in an incubator or technology park 
linked to the university or public sector, or in which a university or research 
institute made an investment. However, in Germany there is a narrower deficit of 
the spin-off type, namely every new company that includes a public sector or 
university employee; or a graduate student as one of the founders, and in which the 
university or research institute made the investment. 
The most important spatial feature of the spin-off type, highlighted by many 
authors (including [14], [15], [16], [17], [18]), there is a tendency to locate it near 
the mother institution. There are two explanation of this trend. The first one refers 
to “hard” location factors – presence of a mother institution, usually a large-sized 
economic entity or scientific, contributes to the benefits of agglomeration, used by 
start-ups [15]. A tailored labor market, the presence of specialized business 
environment institutions or potential partners creates favorable conditions for spin-
off companies in the initial phase of development [14]. The second explanation of 
the phenomenon emphasizes the role of “soft” factors, and in particular 
participation of new spin-off entrepreneurs in local social networks, which is 
related to their previous work in the mother institution. Sorenson [18] recognizes 
local social networks as the most important channel of knowledge flows, and also 
distinguishes two their types: related to the flows of specialist knowledge and 
based on the exchange of information about the local business environment. 
Specialist knowledge, especially hidden knowledge (tacit knowledge), referring to 
personal, practical experiences from work in a given industry, it flows mainly 
through informal channels, in personal time meetings of employees in a specific 
sector. Hence the strong local rooting of her flows [19]. Flows of the second type 
of knowledge are similar channels – mainly through informal meetings, groups and 
social ties. That is why the start-up entrepreneurs have the best information about 
the undeveloped market niches and the resources necessary to conduct profitable 
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activities, if their new company operates in the industry in which they worked 
earlier and is located in a place with a known business environment. 
3. Potential of biotechnology in Poland 
The definition of “biotechnology” presented by the Organization for 
Economic Cooperation and Development (OECD) is divided into two parts: a 
simple description of what biotechnology is and the list of techniques that are used 
in it. According to the Polish equivalent of the OECD definition, proposed by the 
Interdisciplinary Team for Bioeconomy Development within the Ministry of 
Science and Higher Education, “biotechnology is an interdisciplinary field of 
science and technology dealing with the change of living and non-living matter 
through the use of living organisms, their parts or derived from them products, as 
well as models of biological processes to create knowledge, goods and services” 
[20]. According to the list of techniques used in biotechnology, below areas should 
be distinguished: 
 DNA / RNA: genomics, pharmacogenomics, DNA probes, genetic engineering, 
sequencing / synthesis / DNA / RNA amplification, gene expression, antisense 
technology. 
 Proteins and other molecules: sequencing / synthesis / engineering of proteins 
and peptides, improved methods of transporting large molecules of drugs, 
proteomics, isolation and purification, signal transduction, identification of 
cellular receptors. 
 Cells, cell cultures and cell engineering: cell and tissue cultures, tissue 
engineering, cell fusion, vaccines and immunization, embryo manipulation. 
 Genes and RNA vectors: gene therapy, viral vectors. 
 Techniques of biotechnological processes: biosynthesis with the use of bio-
reactors, bioengineering, biocatalysis, bioprocessing, bioleaching, biospulization, 
bleaching with biological agents, bioresprinking, bioremediation, biofiltration. 
 Bioinformatics: creation of genomic / protein databases, modeling of complex 
biological processes, system biology. 
 Nanobiotechnology: application of nano / micro-products tools and processes 
for the construction of devices for biosystems research and in drug transport, 
improvement of diagnostics, etc. 
 
The association of biotechnology industry activists – the European 
Association of Biotechnology Industries EuropeBio (The European Association 
for Bioindustries) proposed the distinction within biotechnology of three 
departments (biotechnology colors) to facilitate monitoring and determine the 
directions and speed of biotechnology development [21]. The proposed approach 
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has been accepted by the OECD and is now widely used by European countries. 
“Colors” of biotechnology means: red – biotechnology related to medicine and health 
protection, used in molecular diagnostics, for the production of medicines – 
biopharmaceuticals and vaccines, includes gene and cell therapies and tissue 
engineering; white – industrial and environmental biotechnology; green – 
biotechnology related to agriculture, including the use of genetic engineering 
methods to improve plant and animal production. In addition, there are two 
additional “colors”: blue – biotechnology of waters, dealing with the protection of the 
water environment of rivers, lakes, seas and oceans; violet – deals with social, legal 
and ethical issues related to biotechnology, including food-related issues genetically 
modified (GMO) or research on cell cultures, as well as issues of patents and protection 
of intellectual property. 
The research potential in the field of biotechnology and pharmacy in Poland is 
created by over 2800 scientists specializing in “life science” (a group of science fields 
that by definition relate to living organisms, including humans, animals and plants) 
and medical sciences, employed in universities and research institutes and also over 
8,000 biotechnology students studying at 50 universities with biotechnology 
specialization (93 faculties). 
Research and development projects concerning biotechnology and the 
pharmaceutical industry are conducted in over 100 scientific institutions. The majority 
of implemented R&D projects in Poland, including over 70% of all biotechnology 
R&D projects, concern the development of innovative products. Poland ranks 10th 
in the world in terms of the number of centers involved in conducting clinical trials 
and the first among the so-called emerging markets (1.6% involved in the world). 
Noteworthy, the Central and Eastern Europe is the largest market for clinical 
trials. The countryʼs attractiveness for clinical research and location of R&D 
activity is determined by: large population of patients, relatively low operating 
costs and cost effectiveness of production, well-prepared staff, significant know-
how in improving generics, great potential for conducting clinical trials and 
growing experience in this area [22]. The scale of market development is also 
evidenced by the fact that business expenses for R&D in Poland have been steadily 
growing for several years [23]. The structure of external expenditures of 
biotechnology companies on research and development activities is also changing. 
In 2011, enterprises allocated almost the entire external expenditure (96.8%) to 
payments to government sector entities, while in 2017 external outlays for R&D 
were directed to entities from all parts of the sector, including the largest part of 
the enterprise sector (50% of external expenditure) [24]. In 2012, internal 
expenditure on activities in the field of biotechnology in enterprises increased by 
37% compared to the previous year, including R&D increased by 73%. The 
structure of expenditures on biotechnology is changing significantly according to 
the conducted activity. Every tenth Polish zloty spent on biotechnology in 
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enterprises was allocated to research and development in 2016, and in 2017 – more 
than every fourth. 
4. Determinants of the development of biotechnology 
spin-offs in Poland 
Currently, biotechnology in Poland is in the early stages of development, and 
the biotechnology market is growing slowly. Despite the huge scientific potential, 
there is no efficient transfer system of the developed solutions to the market. The 
innovation of the biotechnology industry is associated with its high capital 
intensity and high risk, which hinders its development. According to the Central 
Statistical Office (CSO) data, only 184 enterprises operate in the field of 
biotechnology (Fig. 1). Their number, however, grows by leaps and bounds and 
increased by 27% during the year (Fig. 2). Poland has a good scientific base to 
become one of the leaders in this sector in the future, however, representatives of 
biotechnology companies pay attention to the fact that access to capital and the 
regulatory environment remain the main barrier. In 2016, the R&D field of 
biotechnology was conducted by a comparable number of entities from the 
enterprise sector (33.5%), the government sector and private non-profit institutions 
(33.4%), and the higher education sector (31.1%), although the dominant internal 
expenditure on R&D (42.4%) was generated by the government sector and private 
non-profit institutions, and the smallest enterprise sector (22.9%). The highest 
percentage of R&D personnel was employed in the higher education sector (48%). 
There is a greater concentration on basic research than in the government sector 
and private non-profit institutions, with low expenditures on applied research being 
the basis for cooperation with the industry [25]. The main source of funding for all 
research and development in the field of biotechnology in Poland are funds from 
the government sector (57-62%, well above the average level in the EU). Funds 
from abroad financed 31.5% of R&D in the field of biotechnology, almost 2.5 
times more than their share in total R&D in Poland. The funds from the enterprise 
sector constituted only 10.8% of total R&D expenditure in the field of 
biotechnology. The activity in the scope of patent protection was attended by only 
a part of the surveyed entities, as inventions for patent protection in 2015 were 
filed by 35% of entities, and patent protection was obtained by 23% of entities 
[25]. An important limitation of the development of the biotechnology sector is the 
low availability of experienced entrepreneurs and members of the scientific and 
research team who understand what is necessary to establish and develop a successful 
company in the field of biotechnology [26]. 
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For the development of Polish biotechnology spin-offs and start-ups in the 
conditions of global competition, the overall innovation of the economy, processes 
of developing a knowledge-based economy and conditions for the 
commercialization of scientific research in Poland are important. Poland scored 
68.16 points out of 100 on the 2018 Global Competitiveness Report published by the 
World Economic Forum. Competitiveness Index in Poland averaged 15.02 Points 
from 2007 until 2018, reaching an all-time high of 68.16 points in 2018 and a record 
low of 4.28 Points in 2008. The value obtained in the Innovation pillar assessing 
the environment conducive to innovative activity places Poland in the 37th position 
on the 140 countries studied [27]. 
 
 
Fig. 1. Innovation and entrepreneurship centers  
in Poland in 2017 (leading institutions) 
Source: own elaboration based on Beauchamp  
M., Kowalczyk A., Skala A., Polish Startups Report, Warszawa, 2017. 
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Fig. 2. Innovation and entrepreneurship centers  
in Poland between 1993 and 2017 
Source: own elaboration based on Bąkowski A., Marzewska M., Ośrodki innowacji  
i przedsiębiorczości w Polsce. Raport 2018, Poznań-Warszawa 2018, s. 9. 
5. Commercialization of scientific research  
The market (commercialization) of scientific research consists of four areas: 
the supply side (manufacture of inventions by inventors and universities and 
research institutes), the demand side (demand for innovation from entrepreneurs 
and investors), transmission mechanism (matching demand with supply, i.e. 
commercialization of inventions) and market regulation policy (legal regulations, 
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Fig. 3. The market of commercialization  
of scientific researchfor biotechnology spin-offs 
Source: own elaboration based on Białek-Jaworska A., Gabryelczyk R., Perspektywy rozwoju 
przedsiębiorczości akademickiej w branży biotechnologicznej, Warszawa 2014, s. 30. 
Observed in OECD countries trends in the development of the research market 
point to the increasingly important role of proper regulation of intellectual property 
problems, the need to build a culture of innovation and the elimination of barriers 
to entrepreneurship and change the direction of direct research support by 
supporting cooperation between universities, institutes research – entrepreneurs, 
development of start-up companies and increase of venture capital support. It 
seems that the development of the Polish research market in this direction will 
accelerate the development of biotechnology spin-offs, and above all will make 
the process of R&D commercialization more effective and reachable. The most 
important barriers for the commercialization of research results in Poland, also in the 
field of biotechnology, include: limited experience in cooperation between universities 
and scientific institutions with business, weakness of the transmission mechanism, 
insufficiently developed institutions or positions of innovation entrepreneurs 
(science). Additionally, Orłowski [28] mentions the lack of clear principles of 
settling costs and income from commercialization in scientific institutions, internal 
mechanisms blocking commercialization in scientific institutions, availability  
of basic research funding and lack of economic coercion for searching long-term 
commercialization revenues by scientific institutions, as well as lack of effective 
channels of information flow between the supply side and demand. 
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Building models of cooperation between universities and scientific 
institutions with business should be accompanied by the dissemination of best 
practices tested on the Polish market for this cooperation and the use of reference 
solutions used in countries (benchmarking) – innovation leaders. The Ministry of 
Science and Higher Education as part of the “Brokers of Innovation” program 
chose the first 30 people who perform the new brokerage of innovation on the 
Polish market [29]. Their task is to search for research results at universities that 
have market potential and their commercialization. As part of another ministerial 
program “Top 500 Innovators”, young scientists from Polish universities have 
spent several months internships at the best universities in the United States, where 
they learned the best methods of commercialization of research results [29]. 
6. Summary 
In summary, there is a large scientific potential in Poland and there is  
a significant development of the biotechnology sector and enterprises that focus 
on R&D and the creation of innovative solutions in the field of biotechnology. 
Innovation support institutions have also been established, such as technology 
transfer centers or science and technology parks with varying operational 
efficiencies. An obstacle to the even more dynamic development of the biotechnology 
industry seems generally low innovation of the Polish economy, whose roots lie in 
the improper functioning of the market for the commercialization of scientific 
research. 
In order to strengthen the competitive position by increasing the innovativeness 
of the Polish biotechnology sector, it will be important to influence the growth of 
competences of R&D staff. This applies in particular to qualifications in the scope 
of protection of intellectual and industrial value, management of research projects 
and commercialization processes of research results. 
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